PharmaJet Presents Multiple Partners’ Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at BIO International Convention

PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June. The presentation, entitled Improved Vaccine and Therapeutic Performance…without the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.

There is a growing body of evidence that shows needle-free delivery can make injectables perform better. PharmaJet’s Needle-free Injection Systems (NFIS) can improve performance by providing a similar, and often better, immunogenicity in the patient with a strong antibody and T-cell response, when used to administer nucleic acid-based vaccines and therapeutics. Currently there are 18 partner publications that show equivalent or better effectiveness when using the PharmaJet NFIS compared with either electroporation or traditional needle and syringe. These include 11 studies comparing delivery methods for DNA vaccines, 1 for an mRNA vaccine, and 2 for live attenuated vaccines.1

This presentation highlighted published collaborator data from three partners that found increased immunogenicity when using the PharmaJet Systems to deliver nucleic acid-based vaccines:

  1. Zydus Lifesciences recently conducted a non-human primate study on their Plasmid DNA-based COVID-19 vaccine. They saw higher antibody responses with the Tropis® ID System as compared to needle and syringe delivery and better protection from challenge with the virus. After getting similar results in their phase I studies, they progressed to phase II and III exclusively using PharmaJet’s Needle-free Systems and are now commercializing their product.2
  2. INRA compared the results of DNA plasmids administered with needle-free jet injection or electroporation. The Tropis System induced higher luciferase expression, was more potent to transduce skin cells and induced lower inflammatory responses.3
  3. Curevac compared needle and syringe versus needle-free delivery at both ID (using the PharmaJet Tropis® System) and IM (using the PharmaJet Stratis® System) depths for their candidate mRNA-based vaccine that encodes rabies antigen and found the candidate vaccine boosted functional antibodies when humans were injected with a needle-free device but not when injected by a needle-syringe.4

“Our worldwide partner list is quickly growing, and feedback has been very positive,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “With over 80 studies currently in progress with 55 pharmaceutical partners, we’ve learned that a broad variety of pharmaceutical products can be delivered needle-free including nucleic acid-based, inactivated, subunit, live attenuated and viral vector vaccines. We are aiming to increase our pipeline 3-fold in the next several years.”


References

1 Data on file

2 Momin, et al 2021, Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

3 Bernelin-Cottet, et al, A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection

4 Alberer, et al 2017, Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy